Literature DB >> 3037288

Sensitivity in vitro of herpes simplex virus isolates to human fibroblast interferon.

S Leventon-Kriss, M Movshovitz, Z Smetana, M Shewach-Millet, T Doerner, T Gotlieb-Stematsky.   

Abstract

Sensitivity of herpes simplex virus (HSV) isolates, from patients with recurrent infections, to human fibroblast beta interferon (IFN), was tested in vitro. Among 25 HSV strains, 12 were HSV-1, isolated from facial and labial lesions, and 13 were HSV-2 isolated from genital lesions. Viral sensitivity to IFN was examined on epithelial MB cell line by yield reduction and plaque reduction and close correspondence between the two methods was observed. Most of HSV-1 isolates were in the same range of sensitivity to IFN, while HSV-2 isolates varied in sensitivity and differences approached statistical significance (P = 0.14). No correlation was found between various biological properties, such as plaque size, virulence in baby mice, growth at different temperatures, thymidine kinase activity in the presence or absence of IFN and sensitivity to IFN. Application of beta IFN containing cream reduced clinical symptoms in most of the patients. However, larger numbers of patients should be evaluated in order to conclude whether in vitro sensitivity correlates to clinical improvement.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3037288     DOI: 10.1007/BF00193896

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  16 in total

1.  Propagation of human wart virus in tissue culture.

Authors:  M Eisinger; O Kucarova; N H Sarkar; R A Good
Journal:  Nature       Date:  1975-07-31       Impact factor: 49.962

2.  Comparative studies on the inhibitory effects of interferon on various strains of herpes simplex viruses in vitro.

Authors:  J Imanishi; M Matsubara; T Kishida; Y Ozaki; T Kurimura
Journal:  Biken J       Date:  1980-09

3.  Characterization of an herpes simplex virus type 2 mutant, which is resistant to acycloguanosine and causes fusion of BSC1 cells.

Authors:  E Katz; E Margalith
Journal:  Arch Virol       Date:  1982       Impact factor: 2.574

4.  Comparative efficacy of antiherpes drugs against different strains of herpes simplex virus.

Authors:  E De Clercq; J Descamps; G Verhelst; R T Walker; A S Jones; P F Torrence; D Shugar
Journal:  J Infect Dis       Date:  1980-05       Impact factor: 5.226

5.  Combined antiviral effect of interferon and acyclovir on herpes simplex virus types 1 and 2.

Authors:  T L Stanwick; R F Schinazi; D E Campbell; A J Nahmias
Journal:  Antimicrob Agents Chemother       Date:  1981-04       Impact factor: 5.191

6.  Sensitivity of herpes simplex virus types 1 and 2 to three preparations of human interferon.

Authors:  J C Overall; T J Yeh; E R Kern
Journal:  J Infect Dis       Date:  1980-12       Impact factor: 5.226

7.  Thymine salvage, mitochondria, and the evolution of the herpesviruses.

Authors:  G A Gentry; G P Allen; R Holton; R B Nevins; J J McGowan; V Veerisetty
Journal:  Intervirology       Date:  1983       Impact factor: 1.763

8.  Inhibition by interferon of biochemical transformation induced by cloned herpesvirus thymidine kinase genes.

Authors:  H Otsuka; H Qavi; S Kit
Journal:  Antiviral Res       Date:  1982-10       Impact factor: 5.970

9.  Differentiation of herpes simplex virus types 1 and 2 by sensitivity to (E)-5-(2-bromovinyl)-2'-deoxyuridine.

Authors:  D R Mayo
Journal:  J Clin Microbiol       Date:  1982-04       Impact factor: 5.948

10.  Interferon susceptibility of herpes simplex virus strains isolated from patients enrolled in clinical trials.

Authors:  J A Armstrong; M B Skicki-Mullen; M K Breinig; M Ho
Journal:  Antimicrob Agents Chemother       Date:  1983-07       Impact factor: 5.191

View more
  3 in total

1.  Strain-dependent structural variants of herpes simplex virus type 1 ICP34.5 determine viral plaque size, efficiency of glycoprotein processing, and viral release and neuroinvasive disease potential.

Authors:  Hanwen Mao; Ken S Rosenthal
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

Review 2.  The challenge of developing a herpes simplex virus 2 vaccine.

Authors:  Lesia K Dropulic; Jeffrey I Cohen
Journal:  Expert Rev Vaccines       Date:  2012-12       Impact factor: 5.217

Review 3.  Vaccines against Genital Herpes: Where Are We?

Authors:  Hyeon Cheol Kim; Heung Kyu Lee
Journal:  Vaccines (Basel)       Date:  2020-07-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.